Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. The company is headquartered in New York City, New York and currently employs 74 full-time employees. The company went IPO on 2025-01-31. The firm uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization, or HALO, half-life extending platform and its MOMENTUM oral NuSH analog peptide delivery platform to deliver highly differentiated product candidates. Its product pipeline includes MET-097i, MET-233i / MET-233i + MET-097i and MET-224o. MET-097i, its advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA. MET-233i is a subcutaneously injectable ultra-long-acting amylin analog, with enhanced solubility and miscibility with its other NuSH analog peptides. MET-224o is an oral, fully biased ultra-long acting GLP-1 RA. The firm's pipeline also includes MET-002o, MET-AMYo, MET-034i, MET-067i and MET-PYYi.
Follow-Up Questions
Metsera Inc のCEOは誰ですか?
Mr. Christopher Bernard は Metsera Inc の President で、2023 から在籍しています。